HK1072896A1 - G-type peptides to ameliorate atherosclerosis - Google Patents

G-type peptides to ameliorate atherosclerosis

Info

Publication number
HK1072896A1
HK1072896A1 HK05105238.6A HK05105238A HK1072896A1 HK 1072896 A1 HK1072896 A1 HK 1072896A1 HK 05105238 A HK05105238 A HK 05105238A HK 1072896 A1 HK1072896 A1 HK 1072896A1
Authority
HK
Hong Kong
Prior art keywords
peptides
type peptides
ameliorate
atherosclerosis
ameliorate atherosclerosis
Prior art date
Application number
HK05105238.6A
Other languages
English (en)
Inventor
Alan M Fogelman
Mohamad Navab
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1072896A1 publication Critical patent/HK1072896A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
HK05105238.6A 2002-04-05 2005-06-23 G-type peptides to ameliorate atherosclerosis HK1072896A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/120,508 US6930085B2 (en) 2002-04-05 2002-04-05 G-type peptides to ameliorate atherosclerosis
PCT/US2003/009988 WO2003086326A2 (en) 2002-04-05 2003-04-01 G-type peptides to ameliorate atherosclerosis

Publications (1)

Publication Number Publication Date
HK1072896A1 true HK1072896A1 (en) 2005-09-16

Family

ID=28674643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105238.6A HK1072896A1 (en) 2002-04-05 2005-06-23 G-type peptides to ameliorate atherosclerosis

Country Status (9)

Country Link
US (2) US6930085B2 (zh)
EP (1) EP1496930B1 (zh)
JP (1) JP4361809B2 (zh)
CN (1) CN1658893B (zh)
AT (1) ATE516811T1 (zh)
AU (1) AU2003262142C1 (zh)
CA (1) CA2480217C (zh)
HK (1) HK1072896A1 (zh)
WO (1) WO2003086326A2 (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
MXPA05005031A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
EP3254673A1 (en) * 2002-11-13 2017-12-13 The UAB Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
GB0305793D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
US8012483B2 (en) * 2004-04-15 2011-09-06 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
JP2005318829A (ja) * 2004-05-07 2005-11-17 Shigeru Kinoshita 抗菌性ペプチド、該抗菌性ペプチドをコードするポリヌクレオチド、並びに該抗菌性ペプチドを含有する抗菌剤、抗菌性医薬、点眼薬及び眼感染症疾患検査薬
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
AU2005272888A1 (en) * 2004-08-11 2006-02-23 The Regents Of The University Of California Orally administered small peptides synergize statin activity
CN104558200B (zh) * 2004-09-02 2021-11-16 康石医药科技（上海）有限公司 改进的apo e类似物及其使用方法
JP2008513479A (ja) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤
ATE459650T1 (de) * 2004-10-08 2010-03-15 Univ Liege KOMPLEMENTÄRE PEPTIDE FÜR ß-AMYLOID 29-42-PEPTID
JP5091679B2 (ja) 2004-10-15 2012-12-05 アメリカ合衆国 マルチドメイン両親媒性ヘリックスペプチドおよびその使用方法
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
EP1835027B1 (en) * 2004-12-07 2015-02-25 Toray Industries, Inc. Novel cancer antigen peptide and the use thereof
KR20080006617A (ko) 2005-04-15 2008-01-16 백톤 디킨슨 앤드 컴퍼니 패혈증의 진단
SG173373A1 (en) 2005-04-29 2011-08-29 The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1836906B1 (en) * 2006-03-24 2009-07-01 Unilever N.V. Healthy food product
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2008094905A2 (en) * 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032749A2 (en) * 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
US8575107B2 (en) * 2008-01-22 2013-11-05 Compugen Ltd. Clusterin derived peptide
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
CN102307585A (zh) * 2009-03-13 2012-01-04 不二制油株式会社 具有抗动脉粥样硬化作用的二肽
CA2846865A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
RU2651708C2 (ru) * 2011-09-30 2018-04-23 Сомалоджик, Инк. Прогнозирование риска сердечно-сосудистого события и его применение
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
US9103837B2 (en) 2012-11-07 2015-08-11 Somalogic, Inc. Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
BR112017001860A2 (pt) * 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN105061579B (zh) * 2015-08-18 2018-08-28 北京大学人民医院 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
EP3490579A1 (en) 2016-07-27 2019-06-05 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
WO2018063796A1 (en) 2016-09-28 2018-04-05 The Regents Of The University Of California Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism
BR112019024796A2 (pt) 2017-05-26 2020-06-16 Viramatix Sdn Bhd Peptídeos e usos dos mesmos como agentes antivirais

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3933850A1 (de) * 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
ATE171192T1 (de) 1992-06-12 1998-10-15 Innogenetics Nv Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer
WO1994004563A1 (en) 1992-08-14 1994-03-03 Shino-Test Corporation PEPTIDES CONTAINING RESPECTIVE AMINO ACID SEQUENCES SELECTED FROM AMONG THOSE OF LIPOPROTEIN(a) AND APOLIPOPROTEIN(a), ANTIBODIES RESPECTIVELY RECOGNIZING THESE AMINO ACID SEQUENCES, AND METHOD OF ASSAYING WITH THESE ANTIBODIES
CA2150371C (en) * 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
KR19990044460A (ko) 1995-09-09 1999-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU710061B2 (en) 1996-03-29 1999-09-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
IN185761B (zh) 1997-05-13 2001-04-28 Council Scient Ind Res
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU3356899A (en) 1998-03-17 1999-10-11 Uab Research Foundation, The Synthetic peptides that enhance ldl uptake
AU3116800A (en) * 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
BR0108924A (pt) * 2000-03-03 2003-04-29 Smithkline Beecham Biolog Composição umonogênica adaptada para administração a um hospedeiro humano para o tratamento ou prevenção da aterosclerose, vacina, e, método de tratamento ou profilaxia da aterosclerose
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
EP1496930A4 (en) 2006-06-21
US20030191057A1 (en) 2003-10-09
AU2003262142A1 (en) 2003-10-27
EP1496930B1 (en) 2011-07-20
US7638494B2 (en) 2009-12-29
WO2003086326A3 (en) 2004-03-25
US6930085B2 (en) 2005-08-16
CA2480217A1 (en) 2003-10-23
JP4361809B2 (ja) 2009-11-11
ATE516811T1 (de) 2011-08-15
AU2003262142B2 (en) 2009-03-26
AU2003262142C1 (en) 2009-08-13
JP2005536456A (ja) 2005-12-02
US20060258839A1 (en) 2006-11-16
CN1658893A (zh) 2005-08-24
WO2003086326A2 (en) 2003-10-23
CA2480217C (en) 2013-06-25
CN1658893B (zh) 2011-04-06
EP1496930A2 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
HK1072896A1 (en) G-type peptides to ameliorate atherosclerosis
WO2006034056A3 (en) G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
TNSN07396A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DK1318828T3 (da) Oralt administrerede peptider til bedring af aterosklerose
IL162943A0 (en) High chromium-nitrogen bearing castable alloy
DK1423936T3 (da) Meddelelsesrekonstruktion fra partiel detektering
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
AU9502401A (en) Developing applications online
AU2003247967A8 (en) Interactive electronic commerce and message interchange system
HK1151575A1 (zh) 電照明火焰模擬器
PT1551372T (pt) Subunidade de sequestração e composições e métodos relacionados
NO20025370D0 (no) Spermatozopopulasjoner som birer X-kromosom og Y-kromosom av höy renhet
DE60029798D1 (de) Ring zur verformung des magens
NO20044898L (no) Nye etonogestrel estere
DE60335962D1 (de) Bildanzeigeeinheit des projektionstyp
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
DE60331541D1 (de) Gaserzeugende Zusammensetzung
IS7537A (is) Notkun á nýjum etónógestrel esterum.
AU2003256256A8 (en) Bridge terminal output unit
WO2002006478A3 (en) Extracellular matrix protein
TW200608982A (en) Oral formulations of paricalcitol
ES1045770Y (es) Aparato corrector mandibular.
SE0004686D0 (sv) Immediate display message
AU2002252332A1 (en) Online promotional scheme

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180401